NIMHANS study reveals rapid disease progression and shorter survival in Indian Multiple System Atrophy patients compared to global data.

Multiple system atrophy is a rare, progressive neurodegenerative condition for which there is currently no cure.

About Multiple System Atrophy Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement.

Multiple System Atrophy is an orphan disease, with a mean incidence in the US of 0.6:100,000 person-years, increasing with ≥50 years of age to 3:100,000 person-years.

Four patients with Unified Multiple System Atrophy Rating Scale (UMSARS) ≤20 points at baseline were allocated to the moderate stage group.

About Multiple System Atrophy Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement.

The use of proceeds from this financing will provide Alterity a strong balance sheet to fund the necessary non-clinical studies, chemical manufacturing and controls (CMC) activities, clinical and ...

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study in patients ...

Ampreloxetine is being developed to address the root cause of blood pressure instability in multiple system atrophy, aiming to improve patient outcomes and independence.